AD

Tralokinumab-ldrm Therapeutic Cheat Sheet
tralokinumab
by Emily Murphy, MD on
Atopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c …
Tips and Tricks for Diagnosing & Managing Atopic Dermatitis (AD)
atopic dermatitis
by Edita Newton, MD on
Atopic dermatitis is a heterogeneous, chronic inflammatory disease that affects upwards of 10% of children and 7% of adults in the United States. Despite being an incredibly common skin concern among patients, AD continues to pose diagnostic and treatment challenges to dermatologists. What are some common misconceptions about AD? AD always starts in childhood. FALSE. 25% of adults w …
What’s New in Atopic Dermatitis
atopic dermatitis
by NEXT STEPS IN DERM TEAM on
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Adam Friedman (Professor and Chair of Dermatology who serves as Associate Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Program in the GW Department of Dermatology) about the latest in Atopic Dermatitis (AD). Watch as he discu …
JDD Issue Highlights | October 2021 | Special Focus: Atopic Dermatitis
ATOPIC DERMATITIS
by NEXT STEPS IN DERM TEAM on
With a special focus on atopic dermatitis, the October issue of the Journal of Drugs in Dermatology features a great line up of original articles on topics ranging from topical body skincare for toning and tightening, the psychological burden associated with atopic dermatitis, to treatment of toenail onychomycosis in the US and everything in between! Straight from the JDD Editor’s desk, we sha …
Recalcitrant Dyshidrotic Eczema Treated With Dupilumab
eczema
by NEXT STEPS IN DERM TEAM on
The following two cases presented by JDD authors Ryan A. Gall MD, John D. Peters MD, and Alyson J. Brinker MD add to the growing literature supporting the use of dupilumab in the treatment of patients with recalcitrant dyshidrotic eczema, both with and without diagnosed contact allergens. Introduction Dyshidrotic eczema, also known as dyshidrosis or pompholyx when involving larger bullae, is a c …